Related Experiment Video
Updated: May 13, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Melanoma genetics: the other side
1Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA.
Abstract:
Although melanoma has traditionally been regarded as a uniformly fatal malignancy, personalized treatment of this cancer relies on the recognition of its genetic heterogeneity and our ability to pharmacologically target these specific and recurrent changes. Recent advances in the treatment of melanoma have come from the understanding that melanoma is a large family of molecularly distinct diseases. Advances in melanoma genetics and new molecular technology, such as whole-exome and whole-genome sequencing, have lead to unprecedented progress in understanding the key oncogenes and signaling pathways involved in the pathogenesis and progression of melanoma. In addition, we have gained an appreciation for the complexity of such a system with numerous points of cross talk, which has partially impeded our current therapeutic strategies in patients with advanced melanoma. In this review, we focus on the novel discoveries in melanoma genetics and the potential for therapeutic options.
Insights
Melanoma treatment is advancing by recognizing its genetic diversity. Understanding melanoma genetics and signaling pathways offers new therapeutic targets for this complex cancer.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Melanoma was historically viewed as a uniformly fatal cancer.
- Recent understanding highlights melanoma as a group of molecularly distinct diseases, shifting treatment paradigms.
Purpose of the Study:
- To review novel discoveries in melanoma genetics.
- To explore potential therapeutic options targeting specific genetic alterations in melanoma.
Main Methods:
- Review of recent advances in melanoma genetics.
- Integration of findings from whole-exome and whole-genome sequencing technologies.
- Analysis of key oncogenes and signaling pathways in melanoma pathogenesis.
Main Results:
- Melanoma exhibits significant genetic heterogeneity, defining it as a spectrum of diseases.
- Advances in genomic technologies have elucidated critical oncogenic drivers and pathways.
- Complexity and cross-talk within signaling networks present therapeutic challenges.
Conclusions:
- Personalized melanoma treatment necessitates understanding its genetic landscape.
- Targeting specific genetic changes holds promise for improved therapeutic strategies.
- Continued research into melanoma genetics is crucial for developing effective treatments.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancers Originate from Somatic Mutations in a Single Cell
Cancers Originate from Somatic Mutations in a Single Cell
Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...

